RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Octreótido: Uma terapêutica Opcional para Quilotórax Pós-cirúrgico em Crianças com Cardiopatia Congénita = Octreotide: Additional conservative therapy for postoperative chylothorax in congenital heart disease

Auteur(s) / Author(s)

PARAMES Filipa ; FREITAS Isabel ; FRAGATA José ; TRIGO Conceiçao ; PINTO Maria Fatima F. ;

Résumé / Abstract

Introduction: Chylothorax is a rare but serious postoperative condition in children with congenital heart disease. Conventional medical treatment consists of specific long-term dietary modification, and surgical reintervention, such as lymphatic duct ligation, may be indicated in refractory cases. In recent years, an additional conservative treatment, octreotide, a synthetic analog of somatostatin, has been used in management of congenital and postoperative chylothorax. Methods: The objective of this work was to analyze the efficacy and safety of this treatment for chylothorax after congenital heart surgery. We reviewed the records of sixteen patients with chylothorax after surgery for congenital heart disease between January 1999 and December 2007, and collected the following data: demographic information; type of surgical procedure; onset, duration and management of chylothorax and treatment; and duration of hospital stay. To analyze efficacy we compared these parameters in children receiving conventional treatment only with those receiving octreotide. To analyze safety we compared the adverse effects of both treatments. Octreotide was administered at a dose of 4 to 10 μg/kg/hour, with monitoring of side effects. Results: The incidence of chylothorax in our population was 1.6%. It occurred more often after Glenn and Fontan procedures (8 patients). Octreotide was begun three days after diagnosis of chylothorax and continued for a median of seventeen days (ranging from 4 to 26 days), until complete resolution. Side effects were frequent (in 3 of the 8 patients) but of no clinical relevance. All patients responded to the therapy and there was no indication for further surgical intervention. Discussion and Conclusions: Octreotide is safe and effective in the treatment of postoperative chylothorax in children with congenital heart disease. It is a useful adjunetive therapy to the conventional treatment of this complication.

Revue / Journal Title

Revista portuguesa de cardiologia    ISSN  0870-2551 

Source / Source

2009, vol. 28, no7-8, pp. 799-807 [9 page(s) (article)]

Langue / Language

Portugais
Revue : Portugais

Editeur / Publisher

Sociedade Portuguesa de Cardiologia, Lisboa, PORTUGAL  (1982) (Revue)

Mots-clés d'auteur / Author Keywords

Chylothorax

;

Cardiac surgery

;

Octreotide

;

Localisation / Location

INIST-CNRS, Cote INIST : 27222, 35400017005951.0040

Nº notice refdoc (ud4) : 22008849



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas